← All trials
NCT06852573
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2025
- Primary completion
- Feb 20, 2026
- Completion date
- Aug 20, 2027
- First posted
- Feb 28, 2025
- Last posted
- Feb 28, 2025
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Immunochina Medical Science & Technology Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.